Maidenhead, United Kingdom – September 16, 2026 -- CSL Seqirus has published pivotal Phase 3 results for its MF59-adjuvanted, cell-based, higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, reporting superiority over an adjuvanted egg-based comparator across all four influenza strains and age groups tested in a 7,699-participant trial.

Boston – September 16, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) said Chief Financial Officer Tom Fitzgerald is retiring, effective immediately, and will be succeeded on an interim basis by John Tattory.

Toronto – September 16, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the U.S. SEC, enabling the life sciences company to raise up to US$150 million over a 25-month period.

Durham – September 16, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in its global Phase 3 trial testing istaroxime for heart-failure-related cardiogenic shock, a condition with no FDA-approved pharmacologic therapy. The study, RESCUE HF-CS, targets approximately 600 patients recruited at clinical sites across the United States, Europe, China and South America.

London – September 16, 2026 -- Hikma Pharmaceuticals PLC said regulators in the United States, Europe, and the UK have accepted for review its investigational epinephrine nasal spray, a needle-free treatment for anaphylaxis, with an additional filing lodged in Canada.

San Mateo, Calif. – September 15, 2026 -- Helix has launched Whole Exome+ Sequencing (WES+), a diagnostic test that combines exome sequencing, mitochondrial genome analysis, and genome-wide digital karyotype into a single order for patients with unexplained developmental delay, neurological conditions, and rare genetic disease.

Columbia, Md. – September 15, 2026 -- The Foundation Fighting Blindness has renamed its venture philanthropy arm, formerly the Retinal Degeneration Fund (RD Fund), to the Gund Vision Fund, honoring more than 50 years of support from Gordon Gund and the Gund family.

Las Vegas – – September 15, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.

Atlanta – September 15, 2026 -- Medication nonadherence costs the U.S. healthcare system as much as $300 billion annually, a gap Response Media is targeting with the launch of a new health and life sciences practice called RE:HEALTH.

Grand Rapids – September 15, 2026 -- Headlands Research has established a new clinical trial site in Grand Rapids, Michigan, led by board-certified rheumatologist Eric Slavin, MD, FACP, FACR, expanding the network's capacity for rheumatology, autoimmune disease, and cardiometabolic trials in the Midwest.